 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CCX559 / Amgen
Trial termination: A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumors (EUDRACT) - Nov 18, 2023
P1, N=90, Terminated, Sponsor: ChemoCentryx, Inc
Active, not recruiting --> Terminated
- | CCX559 / Amgen
Journal, PD(L)-1 Biomarker, IO biomarker: CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity. (Pubmed Central) - Jun 11, 2023
In a cynomolgus monkey pharmacodynamic study, CCX559 increased plasma levels of soluble PD-L1. These results support the clinical development of CCX559 for solid tumors; CCX559 is currently in a Phase 1, first in patient, multicenter, open-label, dose-escalation study (ACTRN12621001342808).
- CCX559 / Amgen
Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1084;
Additional PD data, together with the safety and PK profile, will be presented. Trial Registration ANZCTR registration ACTRN12621001342808
- CCX559 / Amgen
The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_834;
The in vivo properties of CCX559 suggest that PD-L1 inhibition in tumors may be achieved at relatively low drug levels in the periphery, thus mitigating potential risk of adverse events. No DLTs, treatment-related SAEs or severe (Grade 3 or higher) AEs have been reported in an ongoing first-in-human dose escalation trial with CCX559 (ACTRN12621001342808).
- CCX559 / ChemoCentryx
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors. (Available On Demand; 248) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1653;
Initial results from the phase 1 dose-escalation study of CCX559 indicate on-target PD effects consistent with PD-L1 inhibition. Updated PD data, together with the safety and PK profile, will be presented.
- CCX559 / ChemoCentryx
CCX559, an orally administered small molecule PD-L1 inhibitor for the treatment of solid tumors (Section 34) - Mar 9, 2022 - Abstract #AACR2022AACR_5825;
Prior findings from toxicology studies were consistent with immune modulation, including consumptive coagulopathy, increased white blood cell counts, and changes in IL-6 plasma levels. A Phase 1, first in patient, multicenter, open-label, dose-escalation study was initiated, with a starting dose of once-daily (QD) oral dosing at 30 mg.
- | CCX559 / Amgen
New P1 trial: A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumors (EUDRACT) - Oct 8, 2021
P1, N=90, Recruiting, Sponsor: ChemoCentryx, Inc
- CCX559 / ChemoCentryx
[VIRTUAL] CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity () - Mar 11, 2021 - Abstract #AACR2021AACR_478;
CCX559 prevented PD-L1/PD-1 inhibition of TCR signaling in a cell-based reporter assay, increased IFNγ secretion in allogeneic MLR assays, and increased tumor cell killing by human PBMCs. We demonstrated that CCX559 potentially employs multiple mechanisms to inhibit PD-L1, which are distinct from those published for human anti-PD-L1 antibodies.